New hope for tough cancers: experimental drug shows promise in Late-Stage trial
NCT ID NCT04911907
First seen Apr 15, 2026 · Last updated May 01, 2026 · Updated 2 times
Summary
This study tested a drug called utidelone in 126 people with advanced solid tumors (like stomach, pancreatic, or ovarian cancer) that stopped responding to standard treatments. The goal was to see if the drug could shrink tumors and how safe it was. Researchers measured tumor size changes using scans to determine the response rate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Luhe Hospital, Capital Medical University
Beijing, China
-
Obstetrics and Gynecology Hospital, Capital Medical University
Beijing, China
-
Shanghai East Hospital of Tongji University
Shanghai, China
Conditions
Explore the condition pages connected to this study.